Literature DB >> 31529338

Cell surface-anchored serine proteases in cancer progression and metastasis.

Carly E Martin1,2, Karin List3,4.   

Abstract

Over the last two decades, a novel subgroup of serine proteases, the cell surface-anchored serine proteases, has emerged as an important component of the human degradome, and several members have garnered significant attention for their roles in cancer progression and metastasis. A large body of literature describes that cell surface-anchored serine proteases are deregulated in cancer and that they contribute to both tumor formation and metastasis through diverse molecular mechanisms. The loss of precise regulation of cell surface-anchored serine protease expression and/or catalytic activity may be contributing to the etiology of several cancer types. There is therefore a strong impetus to understand the events that lead to deregulation at the gene and protein levels, how these precipitate in various stages of tumorigenesis, and whether targeting of selected proteases can lead to novel cancer intervention strategies. This review summarizes current knowledge about cell surface-anchored serine proteases and their role in cancer based on biochemical characterization, cell culture-based studies, expression studies, and in vivo experiments. Efforts to develop inhibitors to target cell surface-anchored serine proteases in cancer therapy will also be summarized.

Entities:  

Keywords:  Cancer; Hepsin; Matriptase; Prostasin; TMPRSS2; TMPRSS3; TMPRSS4; Testisin; Type II transmembrane serine proteases

Mesh:

Substances:

Year:  2019        PMID: 31529338      PMCID: PMC6893142          DOI: 10.1007/s10555-019-09811-7

Source DB:  PubMed          Journal:  Cancer Metastasis Rev        ISSN: 0167-7659            Impact factor:   9.264


  221 in total

Review 1.  Possible role of matriptase in the diagnosis of ovarian cancer.

Authors:  Michael D Johnson; Michael D Oberst; Chen-Yong Lin; Robert B Dickson
Journal:  Expert Rev Mol Diagn       Date:  2003-05       Impact factor: 5.225

2.  Sphingosine 1-phosphate, present in serum-derived lipoproteins, activates matriptase.

Authors:  Christelle Benaud; Michael Oberst; John P Hobson; Sarah Spiegel; Robert B Dickson; Chen-Yong Lin
Journal:  J Biol Chem       Date:  2002-01-15       Impact factor: 5.157

3.  Overexpression of testisin, a serine protease expressed by testicular germ cells, in epithelial ovarian tumor cells.

Authors:  K Shigemasa; L J Underwood; J Beard; H Tanimoto; K Ohama; T H Parmley; T J O'Brien
Journal:  J Soc Gynecol Investig       Date:  2000 Nov-Dec

4.  Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer.

Authors:  Jung Y Kang; Marisa Dolled-Filhart; Idris Tolgay Ocal; Baljit Singh; Chen-Yong Lin; Robert B Dickson; David L Rimm; Robert L Camp
Journal:  Cancer Res       Date:  2003-03-01       Impact factor: 12.701

5.  The mechanism of inhibition of antibody-based inhibitors of membrane-type serine protease 1 (MT-SP1).

Authors:  Christopher J Farady; Jeonghoon Sun; Molly R Darragh; Susan M Miller; Charles S Craik
Journal:  J Mol Biol       Date:  2007-04-04       Impact factor: 5.469

6.  A matriptase-prostasin reciprocal zymogen activation complex with unique features: prostasin as a non-enzymatic co-factor for matriptase activation.

Authors:  Stine Friis; Katiuchia Uzzun Sales; Sine Godiksen; Diane E Peters; Chen-Yong Lin; Lotte K Vogel; Thomas H Bugge
Journal:  J Biol Chem       Date:  2013-05-14       Impact factor: 5.157

7.  Pegylated kunitz domain inhibitor suppresses hepsin-mediated invasive tumor growth and metastasis.

Authors:  Wei Li; Bu-Er Wang; Paul Moran; Terry Lipari; Rajkumar Ganesan; Racquel Corpuz; Mary J C Ludlam; Alvin Gogineni; Hartmut Koeppen; Stuart Bunting; Wei-Qiang Gao; Daniel Kirchhofer
Journal:  Cancer Res       Date:  2009-10-20       Impact factor: 12.701

8.  Mutation G827R in matriptase causing autosomal recessive ichthyosis with hypotrichosis yields an inactive protease.

Authors:  Antoine Désilets; François Béliveau; Guillaume Vandal; François-Olivier McDuff; Pierre Lavigne; Richard Leduc
Journal:  J Biol Chem       Date:  2008-02-08       Impact factor: 5.157

9.  Ectopic expression of human airway trypsin-like protease 4 in acute myeloid leukemia promotes cancer cell invasion and tumor growth.

Authors:  Ruhong Yan; Meng Liu; Yae Hu; Lina Wang; Can Wang; Yizhi Jiang; Quansheng Zhou; Xiaofei Qi; Ningzheng Dong; Qingyu Wu
Journal:  Cancer Med       Date:  2019-03-07       Impact factor: 4.452

10.  The Kunitz Domain I of Hepatocyte Growth Factor Activator Inhibitor-2 Inhibits Matriptase Activity and Invasive Ability of Human Prostate Cancer Cells.

Authors:  Shang-Ru Wu; Chen-Hsin Teng; Ya-Ting Tu; Chun-Jung Ko; Tai-Shan Cheng; Shao-Wei Lan; Hsin-Ying Lin; Hsin-Hsien Lin; Hsin-Fang Tu; Pei-Wen Hsiao; Hsiang-Po Huang; Chung-Hsin Chen; Ming-Shyue Lee
Journal:  Sci Rep       Date:  2017-11-08       Impact factor: 4.379

View more
  29 in total

1.  Screening strategy of TMPRSS2 inhibitors by FRET-based enzymatic activity for TMPRSS2-based cancer and COVID-19 treatment.

Authors:  Yeh Chen; Wei-Chien Huang; Chia-Shin Yang; Fang-Ju Cheng; Yi-Fang Chiu; Hsiao-Fan Chen; Thanh Kieu Huynh; Chih-Feng Huang; Chia-Hung Chen; Hsueh-Chun Wang; Mien-Chie Hung
Journal:  Am J Cancer Res       Date:  2021-03-01       Impact factor: 6.166

2.  The Kunitz chymotrypsin inhibitor from Erythrina velutina seeds displays activity against HeLa cells through arrest in cell cycle.

Authors:  Sheyla V Lucena; Fabíola P Rufino; Gioconda Emanuella Diniz de Dantas Moura; Luciana M A Rabêlo; Norberto K V Monteiro; André T Ferreira; Jonas E Aguilar Perales; Adriana F Uchôa; Giselle Z Justo; Caio F R de Oliveira; Ludovico Migliolo; Helena Bonciani Nader; Elizeu A Santos; Adeliana S Oliveira
Journal:  3 Biotech       Date:  2021-12-15       Impact factor: 2.406

3.  Selective targeting of metastatic ovarian cancer using an engineered anthrax prodrug activated by membrane-anchored serine proteases.

Authors:  Nadire Duru; Nisha R Pawar; Erik W Martin; Marguerite S Buzza; Gregory D Conway; Rena G Lapidus; Shihui Liu; Jocelyn Reader; Gautam G Rao; Dana M Roque; Stephen H Leppla; Toni M Antalis
Journal:  Proc Natl Acad Sci U S A       Date:  2022-07-08       Impact factor: 12.779

Review 4.  The Role of Membrane-Associated E3 Ubiquitin Ligases in Cancer.

Authors:  Xuankun Chen; Li Jiang; Zhesheng Zhou; Bo Yang; Qiaojun He; Chengliang Zhu; Ji Cao
Journal:  Front Pharmacol       Date:  2022-07-01       Impact factor: 5.988

Review 5.  Cancer genes and cancer stem cells in tumorigenesis: Evolutionary deep homology and controversies.

Authors:  Vladimir F Niculescu
Journal:  Genes Dis       Date:  2022-04-04

6.  The serine protease matriptase inhibits migration and proliferation in multiple myeloma cells.

Authors:  Ida Steiro; Esten N Vandsemb; Samah Elsaadi; Kristine Misund; Anne-Marit Sponaas; Magne Børset; Pegah Abdollahi; Tobias S Slørdahl
Journal:  Oncotarget       Date:  2022-10-20

7.  The cell-surface anchored serine protease TMPRSS13 promotes breast cancer progression and resistance to chemotherapy.

Authors:  Andrew S Murray; Thomas E Hyland; Kimberley E Sala-Hamrick; Jacob R Mackinder; Carly E Martin; Lauren M Tanabe; Fausto A Varela; Karin List
Journal:  Oncogene       Date:  2020-08-31       Impact factor: 9.867

8.  Matriptase Cleaves EpCAM and TROP2 in Keratinocytes, Destabilizing Both Proteins and Associated Claudins.

Authors:  Chuan-Jin Wu; Michael Lu; Xu Feng; Gaku Nakato; Mark C Udey
Journal:  Cells       Date:  2020-04-21       Impact factor: 6.600

9.  Smoking and COVID-19: Similar bronchial ACE2 and TMPRSS2 expression and higher TMPRSS4 expression in current versus never smokers.

Authors:  Irena Voinsky; David Gurwitz
Journal:  Drug Dev Res       Date:  2020-08-05       Impact factor: 5.004

Review 10.  Dysregulation of Type II Transmembrane Serine Proteases and Ligand-Dependent Activation of MET in Urological Cancers.

Authors:  Shoichiro Mukai; Koji Yamasaki; Masato Fujii; Takahiro Nagai; Naoki Terada; Hiroaki Kataoka; Toshiyuki Kamoto
Journal:  Int J Mol Sci       Date:  2020-04-11       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.